Hepaco 140 Tablet is a hepatoprotective formulation combining L-Ornithine L-Aspartate (250 mg) and Silymarin (70 mg), designed to support liver function and promote hepatic regeneration. L-Ornithine L-Aspartate is an amino acid compound that facilitates ammonia detoxification by enhancing the urea cycle, thereby reducing blood ammonia levels commonly elevated in hepatic encephalopathy and chronic liver diseases. Silymarin, a flavonoid complex extracted from Silybum marianum (milk thistle), exhibits potent antioxidant, anti-inflammatory, and antifibrotic properties, protecting hepatocytes from oxidative stress and toxin-induced damage. The synergistic action of these components aids in improving liver enzyme profiles, enhancing protein synthesis, and accelerating the recovery of liver tissue integrity. Hepaco 140 is indicated for the management of chronic liver disorders such as cirrhosis, hepatitis, and fatty liver disease, as well as for the supportive treatment of hepatic encephalopathy. It is generally well-tolerated, with minimal adverse effects reported. Administration should be as per physician’s guidance, considering patient-specific hepatic function and concomitant therapies. Regular monitoring of liver function tests is recommended to assess therapeutic response and adjust dosage accordingly. Hepaco 140 Tablet represents an effective adjunct in comprehensive liver care aimed at restoring metabolic balance and improving quality of life in patients with hepatic impairment.